Payment overview · 2025
General Payments
$2,370.53
92 reported records · 15 companies
Healthcare provider profile · identity verified
Khai Do, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SANTA ANA, CA · NPI 1396939526
Verified facts
What the public records show
CMS Open Payments records show Khai Do, M.D. received $2,370.53 in general payments during 2025 across 92 reported records.
Amgen Inc. accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Vraylar, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $433.67 | 18.3% | 22 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $402.47 | 17.0% | 18 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $397.63 | 16.8% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $270.89 | 11.4% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $256.58 | 10.8% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $194.34 | 8.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $92.40 | 3.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $90.81 | 3.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.19 | 3.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.51 | 2.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.30 | 1.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.73 | 1.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $22.08 | 0.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.20 | 0.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.73 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,370.53 | 92 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $410.11 | 20 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $402.47 | 18 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $397.63 | 14 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $270.07 | 18 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $256.58 | 7 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $169.99 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $162.23 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $108.66 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $100.81 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $65.82 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.10 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.30 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $11.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 307 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 213 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 107 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
187 | 41 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
213 | 43 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
307 | 65 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
307 | 65 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
107 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 717 | 208 |
| Atorvastatin Calcium | Atorvastatin Calcium | 670 | 199 |
| Metformin Hcl | Metformin Hcl | 366 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 356 | 121 |
| Gabapentin | Gabapentin | 324 | 94 |
| Jardiance | Empagliflozin | 307 | 65 |
| Ezetimibe | Ezetimibe | 267 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 236 | 73 |
| Kerendia | Finerenone | 213 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 60 |
| Farxiga | Dapagliflozin Propanediol | 187 | 41 |
| Simvastatin | Simvastatin | 183 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 167 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 162 | 40 |
| Famotidine | Famotidine | 154 | 40 |
| Alendronate Sodium | Alendronate Sodium | 152 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 152 | 44 |
| Fenofibrate | Fenofibrate,micronized | 136 | 42 |
| Omeprazole | Omeprazole | 119 | 38 |
| Celecoxib | Celecoxib | 117 | 31 |
| Furosemide | Furosemide | 116 | 29 |
| Donepezil Hcl | Donepezil Hcl | 115 | 34 |
| Ozempic | Semaglutide | 115 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 107 | 33 |
| Rybelsus | Semaglutide | 107 | 24 |
| Fenofibrate | Fenofibrate | 104 | 34 |
| Gemfibrozil | Gemfibrozil | 99 | 22 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 97 | 20 |
| Trazodone Hcl | Trazodone Hcl | 97 | 33 |
| Allopurinol | Allopurinol | 96 | 31 |
| Clonidine Hcl | Clonidine Hcl | 91 | 32 |
| Baclofen | Baclofen | 90 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 33 |
| Breo Ellipta | Fluticasone/Vilanterol | 87 | 20 |
| Glipizide | Glipizide | 85 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 81 | 36 |
| Januvia | Sitagliptin Phosphate | 76 | 15 |
| Ibuprofen | Ibuprofen | 74 | 24 |
| Lorazepam | Lorazepam | 64 | 11 |
| Montelukast Sodium | Montelukast Sodium | 63 | 23 |
| Enalapril Maleate | Enalapril Maleate | 62 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | suppressed |
| Azithromycin | Azithromycin | 60 | 48 |
| Atenolol | Atenolol | 59 | 19 |
| Trulicity | Dulaglutide | 57 | suppressed |
| Alprazolam | Alprazolam | 56 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 15 |
| Lisinopril | Lisinopril | 54 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 53 | 21 |
| Finasteride | Finasteride | 47 | 19 |
| Naproxen | Naproxen | 47 | 11 |
| Vraylar | Cariprazine Hcl | 47 | suppressed |
| Carvedilol | Carvedilol | 46 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 44 | suppressed |
| Linzess | Linaclotide | 41 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 14 |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 11 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 38 | 36 |
| Spironolactone | Spironolactone | 38 | 17 |
| Tradjenta | Linagliptin | 38 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 37 | 11 |
| Memantine Hcl | Memantine Hcl | 37 | 11 |
| Meloxicam | Meloxicam | 35 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 35 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 25 | suppressed |
| Fluocinonide | Fluocinonide | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | 12 |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Procto-Med Hc | Hydrocortisone | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Admelog Solostar | Insulin Lispro | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Temazepam | Temazepam | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,370.53 · 92 records | Amgen Inc. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, ELIQUIS, EVENITY, GEMTESA, IBSRELA, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, ZAVZPRET, ZENPEP, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error